经眉弓眶上锁孔入路切除鞍结节脑膜瘤:30 例长期随访的视力结果和复发率分析。

Trans-eyebrow supraorbital keyhole approach to tuberculum sellae meningiomas: a series of 30 cases with long-term visual outcomes and recurrence rates.

机构信息

Departments of Neurosurgery, The Third Affiliated Hospital, Sun Yat-sen University, 600 Tian he Road, Guangzhou, 510630, Guangdong, China.

出版信息

J Neurooncol. 2019 May;142(3):545-555. doi: 10.1007/s11060-019-03128-9. Epub 2019 Feb 22.

Abstract

BACKGROUND

Approach selection paradigm for tuberculum sellae meningiomas (TSMs) is still a point of discussion. The trans-eyebrow supraorbital keyhole approach (TSKA) is a minimally invasive transcranial approach and has been used for the treatment of TSMs during recent years. In this study, we presented a series of 30 cases of TSMs treated via TSKA with a long-term follow-up.

METHOD

Thirty patients with TSMs underwent surgery via TSKA between December 2006 and August 2018. The medical data and follow-up results were retrospectively analyzed.

RESULTS

A total of 5 males and 25 females were included in this study. Three patients presented with recurrent TSMs. The mean tumor size was 25.3 ± 7.3 mm (range, 10-48 mm). The mean follow-up period was 58.0 months (interquartile range, 33.5-86.3 months). Gross total resection (GTR) was achieved in 27 patients (90.0%). One recurrence (3.3%) occurred 9 years after surgery. Out of 29 patients with preoperative visual impairment, 17 (58.6%) improved, eight (27.6%) remained stable, and four (13.8%) deteriorated. No peri-operative death, CSF rhinorrhea, or permanent endocrine dysfunction occurred. All patients exhibited satisfactory cosmetic results. At the last follow-up, the glasgow outcome scale score was five in 27 patients (90.0%).

CONCLUSION

The TSKA is characterized by minimal invasion with a satisfactory cosmetic outcome. Based on the tumor characteristics and surgeon's experience, this approach can be employed as an alternative minimally invasive approach for the treatment of TSMs.

摘要

背景

鞍结节脑膜瘤(TSM)的手术入路选择仍存在争议。眉弓上锁孔入路(TSKA)是一种微创开颅入路,近年来已被用于治疗 TSM。本研究回顾性分析了采用 TSKA 治疗的 30 例 TSM 患者的长期随访结果。

方法

2006 年 12 月至 2018 年 8 月,采用 TSKA 治疗 30 例 TSM 患者。回顾性分析其临床资料和随访结果。

结果

共纳入 5 例男性和 25 例女性患者。其中 3 例为复发性 TSM。肿瘤平均最大径为 25.3±7.3mm(范围 10-48mm)。平均随访时间为 58.0 个月(四分位距 33.5-86.3 个月)。27 例患者达到大体全切除(GTR)。术后 9 年复发 1 例(3.3%)。术前存在视力障碍的 29 例患者中,17 例(58.6%)视力改善,8 例(27.6%)稳定,4 例(13.8%)恶化。无围手术期死亡、脑脊液漏或永久性内分泌功能障碍。所有患者的美容效果均满意。末次随访时,格拉斯哥预后量表评分为 5 分的患者 27 例(90.0%)。

结论

TSKA 具有微创、美容效果满意的特点。根据肿瘤特征和术者经验,该入路可作为治疗 TSM 的一种替代微创入路。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索